Abstract
In Malaysia, co-circulation of CRF01_AE and subtype B has resulted in the emergence of the second generation derivative; CRF33_01B in approximately 20% of its HIV-1 infected individuals. Our objective was to identify possible biological advantages that CRF33_01B possesses over its progenitors. Biological and molecular comparisons of CRF33_01B against its parental subtypes clearly show that CRF33_01B replicated better in activated whole peripheral blood mononuclear cells (PBMCs) and CD4+ T-lymphocytes, but not monocyte-derived macrophages (MDMs). Also, its acquired fitness was greater than CRF01_AE but not subtype B. Moreover, CRF33_01B has higher rate of apoptotic cell death and syncytia induction compared to subtype B. These adaptive and survival abilities could have been acquired by CRF33_01B due to the incorporation of subtype B fragments into the gag-RT region of its full-length genome. Our studies confirm the previously held belief that HIV-1 strains may harbor enhanced biological fitness upon recombination. We therefore estimate a possible gradual replacement of the current predominance of CRF01_AE, as well as wider dissemination of CRF33_01B, together with the identification of other new CRF01_AE/B inter-subtype recombinants in Malaysia.
Keywords: HIV-1 CRF01_AE, HIV-1 subtype B, HIV-1 CRF33_01B, inter-subtype recombinant, biological fitness, Malaysia
Current HIV Research
Title: Evidence for Possible Biological Advantages of the Newly Emerging HIV-1 Circulating Recombinant Form from Malaysia - CRF33_01B in Comparison to its Progenitors _ CRF01_AE and Subtype B
Volume: 8 Issue: 3
Author(s): Katherine A. Lau, Bin Wang, Monica Miranda-Saksena, Ross Boadle, Adeeba Kamarulzaman, Kee-Peng Ng and Nitin K. Saksena
Affiliation:
Keywords: HIV-1 CRF01_AE, HIV-1 subtype B, HIV-1 CRF33_01B, inter-subtype recombinant, biological fitness, Malaysia
Abstract: In Malaysia, co-circulation of CRF01_AE and subtype B has resulted in the emergence of the second generation derivative; CRF33_01B in approximately 20% of its HIV-1 infected individuals. Our objective was to identify possible biological advantages that CRF33_01B possesses over its progenitors. Biological and molecular comparisons of CRF33_01B against its parental subtypes clearly show that CRF33_01B replicated better in activated whole peripheral blood mononuclear cells (PBMCs) and CD4+ T-lymphocytes, but not monocyte-derived macrophages (MDMs). Also, its acquired fitness was greater than CRF01_AE but not subtype B. Moreover, CRF33_01B has higher rate of apoptotic cell death and syncytia induction compared to subtype B. These adaptive and survival abilities could have been acquired by CRF33_01B due to the incorporation of subtype B fragments into the gag-RT region of its full-length genome. Our studies confirm the previously held belief that HIV-1 strains may harbor enhanced biological fitness upon recombination. We therefore estimate a possible gradual replacement of the current predominance of CRF01_AE, as well as wider dissemination of CRF33_01B, together with the identification of other new CRF01_AE/B inter-subtype recombinants in Malaysia.
Export Options
About this article
Cite this article as:
Lau Katherine A., Wang Bin, Miranda-Saksena Monica, Boadle Ross, Kamarulzaman Adeeba, Ng Kee-Peng and Saksena Nitin K., Evidence for Possible Biological Advantages of the Newly Emerging HIV-1 Circulating Recombinant Form from Malaysia - CRF33_01B in Comparison to its Progenitors _ CRF01_AE and Subtype B, Current HIV Research 2010; 8 (3) . https://dx.doi.org/10.2174/157016210791111151
DOI https://dx.doi.org/10.2174/157016210791111151 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clopidogrel in Secondary Ischemic Stroke Prevention
Recent Patents on Cardiovascular Drug Discovery Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Mangiferin – a Bioactive Xanthonoid, not only from Mango and not just Antioxidant
Mini-Reviews in Medicinal Chemistry Structure-Function Relationships of Plasminogen Activator Inhibitor-1 and Its Potential as a Therapeutic Agent
Current Drug Targets GASPIDs <i>Versus</i> Non-GASPIDs - Differentiation Based on Machine Learning Approach
Current Bioinformatics IL-4 and IL-13: Their Pathological Roles in Allergic Diseases and their Potential in Developing New Therapies
Current Drug Targets - Inflammation & Allergy The Role of Kallikrein 7 in Tumorigenesis
Current Medicinal Chemistry In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Neurovascular Complications of Ovarian Hyperstimulation Syndrome (OHSS): From Pathophysiology to Recent Treatment Options
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Pathogenic Role of Foam Cells in Atherogenesis: Do They Represent Novel Therapeutic Targets?
Endocrine, Metabolic & Immune Disorders - Drug Targets Overview on Inhalable Nanocarriers for Respiratory Immunization
Current Pharmaceutical Design Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Chemopreventive Agents Alters Global Gene Expression Pattern: Predicting their Mode of Action and Targets
Current Cancer Drug Targets GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Current Pharmaceutical Design Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Potential of Bone Marrow Stromal Cells in Applications for Neuro-Degenerative, Neuro-Traumatic and Muscle Degenerative Diseases
Current Neuropharmacology The Immunohistochemical Assessment of HPV Related Adenocarcinoma: Pathologic and Clinical Prognostic Significance
Current Pharmaceutical Design Oxidation of Endobiotics Mediated by Xenobiotic-Metabolizing Forms of Human Cytochrome P450
Current Drug Metabolism Drug Conjugated Nanomedicine as Prodrug Carrier
Nanoscience & Nanotechnology-Asia Altered Arginine Metabolism in Cells Transfected with Human Wild-Type Beta Amyloid Precursor Protein (βAPP)
Current Alzheimer Research